CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Helus Pharma Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Helus Pharma Inc.
5600-100 King St West
Phone: (604) 806-0626p:604 806-0626 TORONTO, ON  M5X 1C9  Canada Ticker: HELPHELP
Business Summary
Helus Pharma Inc., formerly Cybin Inc., is a Canada-based clinical stage pharmaceutical company. It is developing proprietary novel serotonergic agonists (NSAs), synthetic molecules designed to activate serotonin pathways to promote neuroplasticity. The Company's proprietary NSAs are intended to address the unmet need for people who suffer from depression, anxiety, and other mental health conditions. The Company is developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. It is also developing HLP004, a proprietary NSA in Phase 2 for generalized anxiety disorder. It has developed EMBARK, which incorporates evidence-based therapies (EBTs), empirically supported treatments (ESTs), and provides session monitors with the training needed to support participants safely and effectively through treatment sessions in clinical trials. Its other pipeline product in development is HLP005.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20263/31/2026YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Eric H.So 51 8/4/2026 11/5/2020
Chief Executive Officer Michael I.Halstead 8/4/2026 8/4/2026
Chief Financial Officer GregCavers 55 11/1/2020 11/1/2020
9 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Small Pharma Ltd 6-8 Bonhill St London United Kingdom
Small Pharma Inc 50 Featherstone Street, 1st Floor LONDON BC United Kingdom

Business Names
Business Name
Adelia Therapeutics Inc.
CX
Cybin Corp.
CYBN
HELP
Small Pharma Ltd

General Information
Number of Employees: 100 (As of 3/31/2026)
Outstanding Shares: 79,592,417 (As of 10/8/2026)
Stock Exchange: NLB
Fax Number: (604) 806-0626


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, October 27, 2026